Ensuring the safety, effectiveness and quality of human drugs is an increasingly complicated regulatory task, requiring FDA’s expert consideration of a multitude of complex factors. Over the past several years, FDA has developed an enhanced structured approach to benefit-risk assessment in regulatory decision-making for human drug and biologic products.
The Benefit-Risk Assessment Framework was developed through extensive review and analysis of previous and ongoing regulatory decisions. PDUFA V commitments include further development and implementation of the Framework into FDA’s human drug and biologic review process. Section 905 of the FDA Safety and Innovation Act also requires FDA to implement a structured benefit-risk framework in the new drug approval process.
In PDUFA V, FDA also committed to a new initiative called Patient-Focused Drug Development with the goal of obtaining the patient perspective on certain disease areas during the five year period of PDUFA V. Assessment of a product’s benefits and risks involves an analysis of the severity of the condition treated and the current treatment options available for the given disease. This information is a critical aspect of FDA’s decision-making as it establishes the context in which the regulatory decision is made. FDA believes that drug development and FDA’s review process could benefit from a more systematic and expansive approach to obtaining the patient perspective on disease severity and current available options in a therapeutic area.
This page contains information related to FDA’s implementation of the PDUFA V commitments regarding enhancing benefit-risk assessment in regulatory decision-making.
Structured Benefit-Risk Assessment
Patient-Focused Drug Development
- PDUFA Federal Register Notices
Webinar: Background on FDA and Patient-Focused Drug Development[ARCHIVED]
- Disease Area Meetings Planned for Fiscal Years 2013-2015
- October 25, 2012 Public Meeting
Patient-Focused Drug Development Consultation Meetings
- The Voice of the Patient
A series of reports from FDA's Patient-Focused Drug Development initiative
Externally-led Patient-Focused Drug Development Meetings